RSC Advances

COMMUNICATION

View Article Online
View Journal | View Issue

Accelerating preclinical PET-screening: reductive amination with [^{11}C]methoxybenzaldehydes†

Cite this: *RSC Adv.*, 2014, **4**, 21347

Received 21st March 2014
Accepted 29th April 2014

DOI: 10.1039/c4ra02506g

www.rsc.org/advances

Matthias M. Herth,*[abc] Sebastian Leth-Petersen,[b] Szabolcs Lehel,[a] Martin Hansen,[b] Gitte M. Knudsen,[c] Nic Gillings,[a] Jacob Madsen[a] and Jesper L. Kristensen[b]

We report, herein, a simple and efficient labelling strategy for multiple PET tracer preparation using a common intermediate, which has the potential to accelerate preclinical PET radiotracer screening. This procedure was applied to and compared with a previously published labelling strategy illustrating the advantages of this newly developed combinatorial approach.

Positron emission tomography (PET) is a powerful non-invasive tool to characterize *e.g.*, receptors, enzymes and other targets *in vivo*. For example, it can be used to quantify receptor binding or receptor occupancy of a given drug at a specific target. For drug discovery processes or disease diagnosis, these outcomes are extremely useful to inform drug development or treatment decisions.[1]

PET tracer development is usually guided by medicinal chemistry structure activity relationship (SAR) studies, where affinity, selectivity towards a certain target and lipophilicity is optimized. Based on these, a few compounds are selected, subsequently labelled and finally evaluated.[1d] Carbon-11 ($t_{1/2}$ = 20.4 min) is often the chosen nuclide for development research due to the possibility to conduct repeated PET studies in the same subject within hours.[2] Traditionally, a last-stage ^{11}C-methylation strategy is applied,[3] whereas multi-step syntheses involving ^{11}C-labelled intermediates are thought to be inferior due the short half-life of carbon-11 and thus lower radiochemical yield (RCY).

We recently developed a carbon-11 labelled radiotracer for the 5-HT$_{2A}$ receptor.[4] During the development phase, we screened 12 ligands synthesised from a classical labelling approach of anisols. This required the synthesis of specific precursors for each tracer resulting in 24 additional precursor synthesis steps (Scheme 1A). Therefore, we became interested in developing a new approach that would provide ready access to this class of tracers and circumvent the need for arduous precursor synthesis. Inspired by the use of ^{18}F-labelled benzaldehydes for ^{18}F-labelling of related compounds (Scheme 1B),[5] we aimed to develop a similar procedure based on an early-stage ^{11}C-labelling of a simple fragment, which could subsequently be coupled to any amine *via* a reductive amination step (Scheme 1C).

We believe that such a 2-step radiosynthesis is advantageous compared to late-stage labelling – in particular in the preclinical



Scheme 1 (A) Classical approach to labelling of anisole derivatives requiring protection of amines. (B) ^{18}F-labelling *via* formation of ^{18}F-benzaldehydes follow by reductive amination of a primary amine. (C) Proposed fusion of the former protocols.

[a]*PET and Cyclotron Unit, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: matthias.herth@nru.dk; Fax: +45 3545 3545; Tel: +45 35458621*

[b]*Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark. Fax: +45 35 33 60 41; Tel: +45 353 36487*

[c]*Center for Integrated Molecular Brain Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Fax: +45 3545 6713; Tel: +45 3545 6711*

† Electronic supplementary information (ESI) available: Experimental procedures, analytical HPLC conditions, semi-prep HPLC conditions, GMP compliant radiosynthesis for Cimbi-36, spectroscopic data for selected compounds. See DOI: 10.1039/c4ra02506g

screening phase, because necessary precursor synthesis steps are minimized since the needed amines already have been prepared during the synthesis of the target compounds. Although this labelling approach has been reported in the literature, it has not been applied to the synthesis of a library of PET-ligands as detailed herein.[6]

Computational approaches to predict the *in vivo* behaviour of radiolabelled compounds based on *in vitro* characteristics are unreliable,[1d,7] and the development of new PET-tracers is still largely a "trial-and-error game".

For example, we recently demonstrated that kinetics, non-specific binding and ultimately the binding potential of 9 structurally related phenethylamines differed quite dramatically, even though the *in vitro* profiles were comparable.[4] Others have also found that small molecular changes to the lead compound have profound effects on the compounds behaviour as a PET-ligand.[8] Thus, rather than just labelling the ligand from a compound series with the best *in vitro* profile, one should investigate several representatives from the same compound class. Ready access to structurally similar PET-ligands with similar pharmacological *in vitro* profiles greatly increases the chance of success.

Only a limited number of studies have been published conducting combinatorial-like multi-step approaches to create PET tracer libraries.[9] For example, Långström and coworkers utilized such a strategy by applying palladium mediated ^{11}C-carbonylations.[9a–c,10] This is surprising since a fast and efficient PET tracer access would facilitate the preclinical evaluation process and probably increase the success rate of novel tracers reaching the clinic.

Therefore, our main goal was to extend the existing combinatorial-like strategy to a 2-step key motif ^{11}C-labelling approach (Scheme 2). Two prerequisites have to be fulfilled for such a procedure.

(1) The labelling of the key motif as well as the subsequent coupling has to be fast and efficient (<10 min, RCY > 50%).

(2) The purification and formulation must be efficient and rapid (<15 min).

Consequently, the total synthesis time should not exceed 40 min and an isolated yield > 300 MBq has to be achievable.

Reductive aminations are fast, efficient and can be conducted chemoselectively.[11] Furthermore, many drugs contain amines and thus a broad variety of target compounds exist which can be synthesized applying this strategy.[12]

To develop this approach, we chose to focus on the labelling of [^{11}C]Cimbi-36, a new PET-tracer for the visualisation of the 5-HT$_{2A}$ receptor in the CNS.[4] The reason for that was twofold: firstly, procedures for radiolabelling methoxybenzaldehydes (MB-CHO) in high radiochemical yields (>80%) and short reaction time (<5 min) are well described.[13]



Scheme 2 This combinatorial labelling approach could provide easy access to a PET tracer library for *in vivo* preclinical evaluation studies by circumventing precursor synthesis for every single PET tracer.



Scheme 3 Comparison of the direct labelling approach (a) with the established labelling procedure *via* (b) and c). (a) $NaBH_3CN$, AcOH, DMSO–MeOH, 130 °C, 5 min. (b) [^{11}C]CH_3OTf, MeCN–acetone, NaOH, 40 °C, 30 s, (c) TFA, MeCN, 80 °C, 5 min.

Table 1 Tested radiolabelling conditions of the novel reductive amination approach for the synthesis of [^{11}C]Cimbi-36

1st key motif labelling (0.3 mL DMSO, [^{11}C]MeOTf)				2nd key motif coupling (0.6 mL MeOH, 5 μL AcOH, 130 °C)			Total yield[a]
2-HBA [mg]	2M NaOH [μL]	Time [s]	Temp. [°C]	2C–B [mg]	$NaBH_3CN$ [mg]	Time [min]	Isolated product [MBq]
2	20	30	25	25	25	5	931
0.3	3	30	25	6	6	5	752
0.1	1	30	25	4	4	5	815
0.1	1	60	25	4	4	5	1684
0.1	1	120	40	4	4	5	226
0.1	1	120	60	4	4	5	230
0.1	1	30	25	4	4	1	20
0.1	1	30	25	4	4	2.5	43

[a] Isolated yield was determined at end of synthesis, see ESI.

Secondly, this would allow us to compare the new approach with a known protocol. In Scheme 3, the established procedure for ^{11}C-labelling *via* alkylation of a Boc-protected precursor along with the proposed reductive amination approach is outlined.

The short half-live of carbon-11 puts severe restrictions on the number and kind of transformations one can conduct after the label has been introduced. Ackermann *et al.* showed that a 2-step reductive amination strategy of a ^{11}C-labelled aniline derivative could be successfully carried out.[6a,14] They utilized this strategy to circumvent side-product formation otherwise observed using a traditional last-step labelling approach. Furthermore, successful reductive aminations of [^{18}F]fluorobenzaldehyde ([^{18}F]FB-CHO) with various amines have been performed in 10–15 min using sodium cyanoborohydride ($NaBH_3CN$).[5] Thus, the proposed reductive amination approach should be feasible for a broad spectrum of amines in the short reaction times required for carbon-11 chemistry (<10 min).

Therefore, we tried to combine the known labelling procedure of 2-[^{11}C]methoxybenzaldehyde (2-[^{11}C]MB-CHO) with the reductive amination conditions for [^{18}F]FB-CHO and applied them to primary phenethylamines,[5,13] which was successful at first. However, several parameters needed optimization: firstly, a 15–20 minute reaction time was detrimental to the RCY and secondly, since relatively large amounts of the precursors were used (25 mg of 2C–B and 2 mg of 2-hydroxybenzaldehyde (2-HBA)), formation of significant amounts of non-radioactive side-products complicated the subsequent purification of the tracer. Therefore, we aimed to optimize and improve these in the next phase.

No influence of precursor concentration on the radiochemical yield of the first labelling step could be detected. Thus, we could successfully lower the amount of precursor to 5% of the original reported procedure. Furthermore, the amount of 2C–B and $NaBH_3CN$ could be reduced, greatly simplifying the final purification. Thus, a successful separation after a 2-step, one-pot reductive amination was achievable (Table 1).

It is worthwhile to mention that the use of glacial acetic acid (AcOH) was essential for the 2nd reaction step and that we were not able to reduce the reaction time for the reductive amination to below 5 min. Insufficient imine and subsequently amine conversion was otherwise observed. Moreover, the use of the less toxic reducing agent sodium triacetoxyhydroborate failed. Finally, we optimized the RCY for the 1st labelling reaction, where the use of [^{11}C]CH_3OTf instead of [^{11}C]CH_3I decreased the reaction time from 5 min to 60 s. Eventually, the optimal conditions were found to be: 1st labelling step: [^{11}C]CH_3OTf, 1 μmol 2-HBA, 2 μmol 2N NaOH, 300 μL DMSO, 25 °C and 60 s; 2nd labelling step: 15 μmol 2C–B, 63 μmol $NaBH_3CN$, 87.5 μmol AcOH, 0.6 mL MeOH, 130 °C, 300 s. Table 1 summarizes the experiments conducted.

In summary, [^{11}C]Cimbi-36 could be labelled in a simple and efficient 2-step, one-pot synthesis within 40 min (yield: 1.6 GBq, specific radioactivity: 60–146 GB μmol^{-1}, radiochemical purity: >99%). Compared with our previous optimized classical 2-step ^{11}C-labelling strategy, the new method usually resulted in ~10–20% lower isolated yield, whereas other parameters were similar. Despite the lowered yield, this novel strategy is more than sufficient to conduct preclinical imaging since usually about 300 MBq is required for an *in vivo* PET scan in larger animals. In regards to a tracer library labelling approach, the synthesis fulfilled the prerequisites and thus, we tested this method on other structurally related phenethylamine structures. Several *ortho*-, *meta*- and *para*-HBA moieties were successfully labelled and subsequently coupled to 2C–B (Scheme 4A).

Moreover, four diverse primary phenethylamines were coupled to 2-[^{11}C]MB-CHO (Scheme 4B). Similar reaction parameters were observed for all conducted experiments and therefore, we believe that this novel combinational 2-component reductive ^{11}C-amination approach is generally applicable



Scheme 4 Standard reductive ^{11}C-amination conditions ($NaBH_3CN$, appropriate R–NH_2, CH_3COOH, DMSO–MeOH, see ESI†) which resulted in an easy access to 8 PET tracers. (A) Coupling of MB-CHO derivatives to 2C–B; (B) coupling of 2-[^{11}C]MB-CHO to different phenethylamine derivatives.

to all kinds of key motif reductive amination approaches and leads, indeed, to an easy tracer library access.

In conclusion, a library of eight phenethylamines was labelled without the need for time consuming precursor synthesis. Thus, we have shown that this novel synthetic library approach, *via* a key radiolabelling intermediate, facilitates preclinical screening by reducing the number of precursor synthesis steps substantially. In a broader perspective, this library approach could be extended to different secondary labelling motifs such as piperazines or piperidines, which are common features in drug molecules.

Acknowledgements

The authors wish to thank the staff at the PET and Cyclotron unit for expert technical assistance. Financial support by the Faculty of Health and Medical Sciences at the University of Copenhagen and the Lundbeck Foundation are gratefully acknowledged.

Notes and references

1 (*a*) L. M. Paterson, B. R. Kornum, D. J. Nutt, V. W. Pike and G. M. Knudsen, *Med. Res. Rev.*, 2013, **33**, 54–111; (*b*) S. M. Ametamey, M. Honer and P. A. Schubiger, *Chem. Rev.*, 2008, **108**, 1501–1516; (*c*) M. E. Phelps, *J. Nucl. Med.*, 2000, **41**, 661–681; (*d*) L. Zhang, A. Villalobos, E. M. Beck, T. Bocan, T. A. Chappie, L. G. Chen, S. Grimwood, S. D. Heck, C. J. Helal, X. J. Hou, J. M. Humphrey, J. M. Lu, M. B. Skaddan, T. J. McCarthy, P. R. Verhoest, T. T. Wager and K. Zasadny, *J. Med. Chem.*, 2013, **56**, 4568–4579.

2 M. M. Herth, V. L. Andersen, S. Lehel, J. Madsen, G. M. Knudsen and J. L. Kristensen, *Chem. Commun.*, 2013, **49**, 3805–3807.

3 (*a*) B. Långström, O. Itsenko and O. Rahman, *J. Labelled Compd. Radiopharm.*, 2007, **50**, 794–810; (*b*) M. Allard, E. Fouquet, D. James and M. Szlosek-Pinaud, *Curr. Med. Chem.*, 2008, **15**, 235–277.

4 A. Ettrup, M. Hansen, M. A. Santini, J. Paine, N. Gillings, M. Palner, S. Lehel, M. M. Herth, J. Madsen, J. Kristensen, M. Begtrup and G. M. Knudsen, *Eur. J. Nucl. Med. Mol. Imaging*, 2011, **38**, 681–693.

5 (*a*) A. A. Wilson, R. F. Dannals, H. T. Ravert and H. N. Wagner, *J. Labelled Compd. Radiopharm.*, 1990, **28**, 1189–1199; (*b*) E. K. Ryu, Y. S. Choe, E. Y. Park, J. P. Paik, Y. R. Kim, K. H. Lee, Y. Choi, S. E. Kim and B. T. Kim, *Nucl. Med. Biol.*, 2005, **32**, 185–191; (*c*) T. Hai-Bin, Y. Duan-Zhi, L. Jun-Ling, Z. Lan, Z. Cun-Fu, W. Yong-Xian and Z. Wei, *Radiochim. Acta*, 2003, **91**, 241–245; (*d*) K. Dahl, M. Schou and C. Halldin, *J. Labelled Compd. Radiopharm.*, 2012, **55**, 455–459; (*e*) D. H. Kim, Y. S. Choe, J. Y. Choi, K. H. Lee and B. T. Kim, *Nucl. Med. Biol.*, 2011, **38**, 541–547.

6 (*a*) U. Ackermann, H. J. Tochon-Danguy, K. Young, J. I. Sachinidis, J. G. Chan and A. M. Scott, *J. Labelled Compd. Radiopharm.*, 2002, **45**, 157–165; (*b*) U. Ackermann, H. J. Tochon-Danguy, M. Nerrie, E. C. Nice, J. I. Sachinidis and A. M. Scott, *Nucl. Med. Biol.*, 2005, **32**, 323–328.

7 Q. Guo, M. Brady and R. N. Gunn, *J. Nucl. Med.*, 2009, **50**, 1715–1723.

8 L. Lemoine, J. Andries, D. Le Bars, T. Billard and L. Zimmer, *J. Nucl. Med.*, 2011, **52**, 1811–1818.

9 (*a*) O. Aberg and B. Långström, *J. Labelled Compd. Radiopharm.*, 2012, **55**, 477–483; (*b*) O. Rahman and B. Långström, *J. Labelled Compd. Radiopharm.*, 2007, **50**, 1192–1199; (*c*) O. Ilovich, O. Aberg, B. Långström and E. Mishani, *J. Labelled Compd. Radiopharm.*, 2009, **52**, 151–157; (*d*) L. N. Jia, Z. Cheng, L. L. Shi, J. B. Li, C. Wang, D. W. Jiang, W. Zhou, H. Meng, Y. J. Qi, D. F. Cheng and L. Zhang, *Appl. Radiat. Isot.*, 2013, **75**, 64–70.

10 B. Långström, P. E. Andren, O. Lindhe, M. Svedberg and H. Hall, *Mol. Imag. Biol.*, 2007, **9**, 161–175.

11 A. F. Abdel-Magid and S. J. Mehrman, *Org. Process Res. Dev.*, 2006, **10**, 971–1031.

12 J. J. Li and D. S. Johnson, *Modern Drug Design*, Wiley, 2010, pp. 1–376.

13 G. Henriksen, M. Schottelius, T. Poethko, A. Hauser, I. Wolf, M. Schwaiger and H. J. Wester, *Eur. J. Nucl. Med. Mol. Imaging*, 2004, **31**, 1653–1657.

14 U. Ackermann, K. Ardipradja, F. T. Lee, H. J. Tochon-Danguy, K. Young and A. M. Scott, *J. Labelled Compd. Radiopharm.*, 2005, **48**, S132.

